CA2970840A1 - Vaccine composition comprising truncated varicella zoster virus glycoprotein e antigen - Google Patents

Vaccine composition comprising truncated varicella zoster virus glycoprotein e antigen Download PDF

Info

Publication number
CA2970840A1
CA2970840A1 CA2970840A CA2970840A CA2970840A1 CA 2970840 A1 CA2970840 A1 CA 2970840A1 CA 2970840 A CA2970840 A CA 2970840A CA 2970840 A CA2970840 A CA 2970840A CA 2970840 A1 CA2970840 A1 CA 2970840A1
Authority
CA
Canada
Prior art keywords
vaccine
immunogenic
years
composition according
vzv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2970840A
Other languages
English (en)
French (fr)
Inventor
Thomas Charles Heineman
Edouard Guy Christian Ledent
Nicolas Pierre Fernand Lecrenier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201503266A external-priority patent/GB201503266D0/en
Priority claimed from GBGB1518917.8A external-priority patent/GB201518917D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CA2970840A1 publication Critical patent/CA2970840A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA2970840A 2014-12-18 2015-12-16 Vaccine composition comprising truncated varicella zoster virus glycoprotein e antigen Pending CA2970840A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB201422686 2014-12-18
GB1422686.4 2014-12-18
GB201503266A GB201503266D0 (en) 2015-02-26 2015-02-26 Vaccination
GB1503266.7 2015-02-26
GB1518917.8 2015-10-26
GBGB1518917.8A GB201518917D0 (en) 2015-10-26 2015-10-26 Vaccination
PCT/EP2015/079967 WO2016096968A1 (en) 2014-12-18 2015-12-16 Vaccination

Publications (1)

Publication Number Publication Date
CA2970840A1 true CA2970840A1 (en) 2016-06-23

Family

ID=54937057

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2970840A Pending CA2970840A1 (en) 2014-12-18 2015-12-16 Vaccine composition comprising truncated varicella zoster virus glycoprotein e antigen

Country Status (8)

Country Link
US (1) US20180008700A1 (enExample)
EP (1) EP3233118A1 (enExample)
JP (1) JP2018500322A (enExample)
CN (1) CN107106675A (enExample)
BR (1) BR112017012647A2 (enExample)
CA (1) CA2970840A1 (enExample)
MX (1) MX2017008055A (enExample)
WO (1) WO2016096968A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201803360UA (en) * 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
CN110582282A (zh) 2017-04-25 2019-12-17 佐剂技术公司 三萜皂苷类似物
US20210187098A1 (en) * 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
CN112189017B (zh) * 2018-05-23 2024-12-27 财团法人牧岩生命科学研究所 水痘带状疱疹病毒的抗原变体及其用途
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
AU2020379738A1 (en) * 2019-11-05 2022-04-14 Adjuvance Technologies, Inc. Varicella zoster
US12569553B2 (en) 2020-03-09 2026-03-10 Dynavax Technologies Corporation Shingles vaccines comprising a TLR9 agonist
US20250325656A1 (en) * 2022-05-20 2025-10-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物

Also Published As

Publication number Publication date
US20180008700A1 (en) 2018-01-11
JP2018500322A (ja) 2018-01-11
WO2016096968A1 (en) 2016-06-23
CN107106675A (zh) 2017-08-29
MX2017008055A (es) 2017-09-28
EP3233118A1 (en) 2017-10-25
BR112017012647A2 (pt) 2018-01-09

Similar Documents

Publication Publication Date Title
US20180008700A1 (en) Vaccination
Heineman et al. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine
US20210187098A1 (en) Vaccination
CA2797937C (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AU2011343368C1 (en) Mycobacterium antigenic composition
ES2787455T3 (es) Vacunas para el VHS-2
AU734443B2 (en) Vaccines
US20120093921A1 (en) Immunogenic compositions having low sodium chloride concentration
EP3125929B1 (en) Novel methods for inducing an immune response
CA3085975A1 (en) Epstein-barr virus antigen constructs
CA3157372A1 (en) Varicella zoster
KR20180039739A (ko) 융합 단백질
BE1022523B1 (fr) Vaccination
KR20210151788A (ko) 백신 보조제 및 제형
US12343388B2 (en) Clostridioides difficile TcdB variants, vaccines and methods of use
Cunningham et al. Herpes Zoster Vaccines: What's New?
Kuipers et al. The immunogenicity of recombinant zoster vaccination in patients with secondary immunodeficiencies: a literature review
WO2023183136A1 (en) Composition comprising antigen and dna and use thereof
TW202436326A (zh) 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者
HEINEMAN Herpes Zoster Vaccines: What’s New?
CN116635521A (zh) 减毒的猪流行性下痢病毒
WO2012085603A2 (en) Dna sensors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201207

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250305

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: WITHDRAW EXAMINER'S REPORT REQUEST RECEIVED

Effective date: 20250312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250912

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260616